Spotlight On... Sanofi cuts research staffers in Boston as reorganization looms: report; Laura Glimcher to head Dana-Farber; Big Pharma pack joins Parkinson's R&D consortium; Soon-Shiong buying up more Phoenix property; and more...

Sanofi ($SNY) is cutting more than 30 lab workers in its Boston hub, according to The Boston Globe. Citing staffers, the report notes that the jobs are being axed in groups that were part of the Genzyme organization acquired by Sanofi. The layoffs may presage more cuts as Sanofi is rumored to be readying a company-wide reorganization, which includes cutting hundreds of unfilled job openings in France. Report

@FierceBiotech: Ignyta dumps some Teva cancer drugs to focus on its top prospects. Report | Follow @FierceBiotech

@JohnCFierce: Incredible what a horrible, awful, no good year this has been for Duchenne MD patients and families. Nothing but rout and disaster. | Follow @JohnCFierce

> Weill Cornell's Laura Glimcher has been named CEO of the Dana-Farber Cancer Institute, one of the leading research centers in the world. Release

> AbbVie ($ABBV), AstraZeneca ($AZN), Biogen ($BIIB), Eli Lilly ($LLY), Pfizer ($PFE) and Merck ($MRK) have all joined a new consortium aimed at finding new drugs for Parkinson's disease. Release

> Biotech billionaire and cancer drug developer Patrick Soon-Shiong has been adding to his real estate portfolio in downtown Phoenix. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA advisory panel votes against recommending approval of Medtronic spine implant. Article | Follow @FierceMedDev

@StacyALawrence: Philips unveils wearable, wireless vitals patch that goes from hospital to home. Story | Follow @StacyALawrence

@EmilyWFierce: op employers aim at Big Pharma with group project to bring down drug costs. More from FiercePharma | Follow @EmilyWFierce

> ResMed to offer its customers software-based services thanks to $800M purchase of Brighttree. More

> Vaginal ring shields some women from HIV in NIH-backed study. Article

Pharma News

@FiercePharma: Japan's MHLW to review 3 drugs, 2 devices for Sakigake list. FiercePharmaAsia article | Follow @FiercePharma

> Those PBM moves pharma loves to hate? They work, CVS says--so get used to them. More

> Prosecutors raid Novartis South Korea in kickbacks probe. Story

> Pfizer workers, retirees face big tax bills from $160B Allergan deal. Report

> Another snafu for Valeant as internal probe triggers restated earnings. Article

Pharma Manufacturing News

> FDA allows banned China plant to ship chemo API that is in short supply. More

> China halts track-and-trace project because of complains against Alibaba. Item

> GSK opens expanded operations, adds 55 jobs, in Scotland. Report

> EMA cites another China plant for manufacturing, data flaws. Story

> Zydus Cadila gets 'first' FDA approval to ship from Ahmedabad plant. Article

Drug Delivery News

> FDA approves UCB epilepsy med, allows administration without titration. Report

> Saudi researchers show linking drugs to nanotubes helps them battle breast cancer. Story

> Two HIV-preventing vaginal ring studies promise protection for women in developing countries. More

> Amgen gets rights to Unilife's wearable and injectable devices for $75M. Item

> Capsugel to manufacture inhaled particle candidates developed by Pulmatrix. Article

Pharma Asia News

> Japan's MHLW to review 3 drugs, 2 devices for Sakigake list. Item

> BMS PhIII hep C combo results a milestone for China plans. More

> Novartis South Korea office target of bribery probe. Report

> China's IMPACT Therapeutics raises $10M in Series B funding. Story

> China's system to track fake drugs put on hold, CFDA says. Article

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i